Chlamydia Trachomatis NAA Test

Most chlamydia infections cause no symptoms at all. They sit quietly in the genital tract, throat, or rectum for months or years, and the only way to know you have one is to test for it. Untreated, this infection is a leading cause of pelvic inflammatory disease, infertility, and ectopic pregnancy in women, and it spreads silently between partners the entire time.

This urine NAAT (nucleic acid amplification test) looks for the actual DNA or RNA of the bacterium Chlamydia trachomatis. It is the most sensitive method available, catching infections that older antigen tests, cultures, and DNA probes routinely miss.

What This Test Actually Detects

A NAAT (nucleic acid amplification test) copies the genetic material of Chlamydia trachomatis millions of times over so that even a tiny amount of bacteria becomes detectable. The result is qualitative: positive means the bacterium's DNA or RNA is present at the sampled site, negative means it is not detectable. There is no "high" or "low" number to interpret.

Because this test uses urine, it captures urogenital infections in both men and women without requiring a swab. Urine NAATs reach roughly 94 to 100 percent sensitivity and 98 to 100 percent specificity for chlamydia detection, comparable to cervical or vaginal swab testing.

One important limitation: a urine test only screens the urogenital tract. If you have rectal or oropharyngeal exposure, those sites need their own swab samples. Studies in women with urogenital chlamydia found that about two-thirds also had rectal infection, and a small percentage had rectal infection despite a clean urine result.

Why It Matters: Pelvic Inflammatory Disease and Infertility

Untreated chlamydia is the single most common preventable cause of pelvic inflammatory disease (PID), an infection that scars the fallopian tubes and increases the risk of infertility, ectopic pregnancy, and chronic pelvic pain. The longer the bacterium sits in the upper genital tract, the more damage it can do.

A retrospective Danish cohort of 272,105 women showed why test quality matters here. Women whose chlamydia was tested with a less sensitive non-NAAT method had a 17 percent higher adjusted risk of subsequent PID after a negative result compared with women tested by NAAT. The implication: missed infections from inferior tests translate directly into more reproductive complications.

Why It Matters: Pregnancy and Newborn Health

Chlamydia during pregnancy raises the risk of preterm birth, low birth weight, neonatal conjunctivitis, and infant pneumonia. A review of 15 studies found that 13 supported a benefit from antenatal chlamydia screening and treatment in reducing these adverse outcomes. The earlier the infection is caught, the more options exist to treat it before it reaches the baby.

Why It Matters: Silent Spread

More than 70 percent of infections in women and around 50 percent in men cause no symptoms. Without testing, you have no way to know whether you are infected or whether you are passing it to partners. NAAT screening of asymptomatic people in higher-risk groups (young adults, sexually active people with new partners, men who have sex with men, sex workers) consistently identifies large numbers of otherwise-undetected infections.

How NAAT Compares to Other Chlamydia Tests

Not all chlamydia tests are equal. The differences between methods can mean the difference between catching an infection and missing it entirely.

What this means for you: a generic STI panel or rapid antigen test is not equivalent to a NAAT. Antigen-based point-of-care tests can miss 40 to 60 percent of infections that a NAAT would catch. If you want a definitive answer, the test method matters as much as the fact of testing.

How to Read Your Result

NAATs are reported as positive or negative. There are no quantitative reference ranges or risk tiers from major guidelines. The result is binary because the clinical question is binary: do you have a current infection that needs treatment, or not?

• Negative: No chlamydia DNA or RNA detected at the sampled site. In a person with no symptoms and no recent exposure, this is reassuring. It does not, however, rule out infection at unsampled sites (rectum, throat) if those exposures occurred.
• Positive: Chlamydia genetic material is present, indicating current or very recent infection. Standard treatment is a course of antibiotics, typically doxycycline, which clears the bacterium in nearly all cases.
• False negatives: Rare, but possible. NAATs can miss certain variant strains that lack the genetic target the assay uses. Sampling too soon after exposure (within the first 1 to 2 weeks) can also produce a negative result before the bacterial load is detectable.

When Results Can Be Misleading

Most factors that affect NAAT accuracy are pre-analytical and largely under your control. The most important things to know:

• Recent antibiotic use: if you have taken antibiotics in the past few weeks for any reason, the bacterial load may be suppressed below the test's detection limit even if infection is still present.
• Testing too soon after exposure: chlamydia takes time to multiply to detectable levels. If you test within a few days of a possible exposure, a negative result may not be reliable. A repeat test 2 to 3 weeks later is more dependable.
• Test of cure timing: chlamydia DNA can persist for weeks after successful treatment, so testing too early after antibiotics can produce a positive result that does not reflect active infection. Guidelines suggest waiting at least 3 weeks before retesting.
• Site mismatch: a urine test does not screen the rectum or throat. If you have had receptive anal or oral exposure, ask for site-specific swabs. Two-thirds of women with urogenital chlamydia in one study also had rectal infection.

Tracking Your Trend

For chlamydia, retesting matters more than tracking a number, because the test is binary and the infection is curable. Three retesting moments are worth knowing about.

• Test of cure (after a positive result): wait at least 3 weeks after finishing antibiotics before retesting. Earlier than that, lingering bacterial DNA can cause a false positive.
• Test of reinfection: even after successful treatment, reinfection from an untreated partner is common. Most guidelines recommend repeat testing about 3 months after treatment.
• Routine screening: if you are sexually active with new or multiple partners, annual NAAT screening is the minimum. Every 3 to 6 months is more appropriate if your exposure profile is higher, regardless of symptoms.

What to Do If Your Result Is Positive

A positive NAAT calls for action, not panic. The bacterium is curable with a short course of oral antibiotics, and the immediate priorities are clear:

• Get treated. Standard first-line therapy is doxycycline 100 mg twice daily for 7 days. This regimen is effective and inexpensive.
• Notify partners. Anyone you have had sexual contact with in the past 60 days should be tested and treated, even if they have no symptoms. Untreated partners are the leading cause of reinfection.
• Test for other STIs. Chlamydia often travels with gonorrhea, trichomonas, and HIV. A full STI workup is reasonable at the same visit.
• Abstain or use protection until both you and any current partners have completed treatment, typically 7 days after starting antibiotics.
• Retest in 3 months to check for reinfection.